Lars H. Genieser, Ph.D.


Lars Genieser anticipates and develops creative solutions to patenting challenges for his technology-driven clients.

Nixon & Vanderhye Shareholder Lars Genieser, Ph.D. is a Registered Patent Attorney active in the pharmaceutical, chemical, and material sciences industries.  He is engaged in a broad range of patent prosecution and counseling activities including application preparation and filing, office action response drafting, preparation of responses and advocacy in oppositions, opinion drafting, and patent portfolio development and management in the U.S. and globally.  Lars counsels clients on identifying and defining inventions, worldwide patent protection strategies, complex inventorship and ownership questions, and risk analysis. 


Lars pursues and obtains patents and manages patent portfolios for pharmaceutical compounds (large molecules (biologics) and small molecules), including oncologic drugs, antibodies, antibiotics, ion channel regulators, analgesics, drugs for treatment of bone disorders, antiemetics, and neuroprotective agents, vaccines, formulations of plant-derived active pharmaceutical ingredients, pharmaceutical formulations, pharmaceutical polymorphs, epigenetics, controlled and targeted pharmaceutical release systems, polymer-metal composite particles, nanotechnology, organometallic chemistry, quantum dots, bioinformatics, pesticides, novel polymers, coatings, cosmetics, electrochemistry, water purification, and chemical and materials processes for pharmaceutical and industrial manufacturing. For example, he developed and manages a complex international patent portfolio for a successful cancer treatment drug.


Lars is experienced in responding to and prevailing over pre-grant and post-grant patent oppositions, obtaining Patent Term Extensions and Supplementary Protection Certificates in the U.S. and abroad, rendering opinions on patentability, freedom-to-operate, patent validity, and license scope, and preparing patent licenses.  His clients include major research universities, large companies, and start-up enterprises.  Lars brings a practical and business-oriented approach to counseling clients at all stages of the patenting and technology-monetization process.


Lars was awarded a Ph.D. in Chemical Engineering by the Massachusetts Institute of Technology and conducted postdoctoral research at the Eindhoven University of Technology in the Netherlands as an NSF-NATO Postdoctoral Fellow.  He is fluent in German.


  • Virginia
  • District of Columbia
  • U.S. Patent and Trademark Office
  • J.D., Georgetown University Law Center, 2006
  • Ph.D., Massachusetts Institute of Technology, 1997
  • German Academic Exchange Service (DAAD) Fellowship, Heinrich Heine University of Düsseldorf, 1990
  • B.S., Chemical Engineering, summa cum laude , Princeton University, 1989
  • L.H. Genieser (Sept. 2021) What patent practitioners can learn from Nalpropion Pharmaceuticals, Inc. v. Actavis Laboratories FL, Inc.  J. Intell. Prop. L. & Pract. 16(9), 1000-1005.
  • L.H. Genieser (May 2019) Drafting a Single Patent Application for Success in the US, Japan, China, and India. AIPLA 2019 Spring Meeting, Philadelphia, PA.
  • L.H. Genieser & M.E. Jung (Aug. 2017) From Discovery to Blockbuster: Patent Strategies for Novel Therapeutics.  California NanoSystems Institute (CNSI) at UCLA.
  • L.H. Genieser (Mar. 2013) Realizing Value Through Patents. Webinar for LARTA Institute.
  • F. Königbauer & L.H. Genieser (Dec. 2012) Supreme Court to Consider Whether (Isolated) Human Genes are Patentable.  IP Buzz.
  • L.H. Genieser & C.E. McCann (Sept. 2012) Obtaining, Challenging and Enforcing Pharmaceutical Patents Under the America Invents Act.  Pharma. Pat. Analyst 1(4), 415-426.
  • L.H. Genieser (Aug. 2012) Veränderung im U.S. Patentrecht Veranlasst Durch das "American Invents Act" von 2011. German language presentation, IPAL, Berlin, Germany.
  • L.H. Genieser (Mar. 2012) Falana v. Kent State Univ.: Determining the Inventorship of Chemical Compounds. IP Buzz.
  • L.H. Genieser (Aug. 2011) Federal Circuit Finds DNA Molecules Patentable in Widely Publicized Myriad Gene Patent Dispute. IP Buzz.
  • C.E. McCann, C.J. Morton & L.H. Genieser (May 2011) Effective Use of Patents to Raise Capital and Protect R&D. Dayton Water Conf., Dayton, OH.
  • L. Genieser & H. Daley (2008) Oxonica v. Neuftec: Nanoparticle Fuel Additive Litigation in the United Kingdom. Nanotech. Law & Bus. 5(3).
  • L. Genieser & M. Gollin (2007) Intellectual Property Issues in Nanotechnology. J. Comm. Biotech. 13(3), 195-198.
  • Washington, D.C. "Rising Star" by Thomson Reuters for 2014-2016
  • American Intellectual Property Law Association
  • American Chemical Society
  • Sigma Xi Honorary Scientific Research Society
  • Member of Advisory Council of Princeton University Department of Chemical & Biological Engineering

Get To Know Lars

What are your hobbies?

Enjoying time with my family, skiing, and traveling.

What inspires you?

Nature and technical innovation.